These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31014274)

  • 1. A preliminary investigation of circulating extracellular vesicles and biomarker discovery associated with treatment response in head and neck squamous cell carcinoma.
    Rodrigues-Junior DM; Tan SS; de Souza Viana L; Carvalho AL; Lim SK; Iyer NG; Vettore AL
    BMC Cancer; 2019 Apr; 19(1):373. PubMed ID: 31014274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating extracellular vesicle-associated TGFβ3 modulates response to cytotoxic therapy in head and neck squamous cell carcinoma.
    Rodrigues-Junior DM; Tan SS; Lim SK; Leong HS; Melendez ME; Ramos CRN; Viana LS; Tan DSW; Carvalho AL; Iyer NG; Vettore AL
    Carcinogenesis; 2019 Dec; 40(12):1452-1461. PubMed ID: 31436806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of MLANA in the plasma of patients with head and neck squamous cell carcinoma as a predictor of tumor progression.
    Rodrigues-Junior DM; Tan SS; Lim SK; de Souza Viana L; Carvalho AL; Vettore AL; Iyer NG
    Head Neck; 2019 May; 41(5):1199-1205. PubMed ID: 30803092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
    Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
    Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma.
    Park MJ; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
    Eur J Cancer; 2018 Mar; 92():69-76. PubMed ID: 29428866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
    Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
    Chang CL; Yuan KS; Wu SY
    Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94).
    Ghadjar P; Pöttgen C; Joos D; Hayoz S; Baumann M; Bodis S; Budach W; Studer G; Stromberger C; Zimmermann F; Kaul D; Plasswilm L; Olze H; Bernier J; Wust P; Aebersold DM; Budach V
    Strahlenther Onkol; 2016 Aug; 192(8):552-60. PubMed ID: 27323753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do circulating long non-coding RNAs (lncRNAs) (LincRNA-p21, GAS 5, HOTAIR) predict the treatment response in patients with head and neck cancer treated with chemoradiotherapy?
    Fayda M; Isin M; Tambas M; Guveli M; Meral R; Altun M; Sahin D; Ozkan G; Sanli Y; Isin H; Ozgur E; Gezer U
    Tumour Biol; 2016 Mar; 37(3):3969-78. PubMed ID: 26482616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-lymphocyte ratio: Prognostic indicator for head and neck squamous cell carcinoma.
    Rosculet N; Zhou XC; Ha P; Tang M; Levine MA; Neuner G; Califano J
    Head Neck; 2017 Apr; 39(4):662-667. PubMed ID: 28075517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy.
    Moon H; Roh JL; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
    Radiother Oncol; 2016 Feb; 118(2):330-4. PubMed ID: 26653356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of computed tomography in the management of the neck after chemoradiotherapy in patients with head-and-neck cancer.
    Clavel S; Charron MP; Bélair M; Delouya G; Fortin B; Després P; Soulières D; Filion E; Guertin L; Nguyen-Tan PF
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):567-73. PubMed ID: 21310545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Extracellular Vesicles-Derived miR-99a-5p: A Potential Biomarker to Predict Early Head and Neck Squamous Cell Carcinoma.
    Huang Q; Shen YJ; Hsueh CY; Zhang YF; Yuan XH; Zhou YJ; Li JY; Lin L; Wu CP; Hu CY
    Pathol Oncol Res; 2022; 28():1610699. PubMed ID: 36330052
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
    Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
    Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
    Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
    Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
    Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis.
    Kim R; Hahn S; Shin J; Ock CY; Kim M; Keam B; Kim TM; Kim DW; Heo DS
    Cancer Res Treat; 2016 Jul; 48(3):907-16. PubMed ID: 26582394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer.
    Cirauqui B; Margelí M; Quiroga V; Quer A; Karachaliou N; Chaib I; Ramírez JL; Muñoz A; Pollán C; Planas I; Drozdowsky A; Rosell R
    Tumour Biol; 2016 Oct; 37(10):13435-13443. PubMed ID: 27465548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
    Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is Lipidomic the Answer to the Search of a Biomarker for Organ Preservation Protocol in Head and Neck Squamous Cell Carcinoma?
    Laus AC; da Silva IDCG; Cordeiro FB; Lo Turco EG; de Souza Viana L; Carvalho AL
    Pathol Oncol Res; 2018 Oct; 24(4):931-935. PubMed ID: 29130149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.